Integrin alpha V beta 3 expression by bone-residing breast cancer metastases

Area of Science:

• Oncology
• Cell Biology
• Biochemistry

Background:

• Breast cancer metastasis to bone is a complex process involving tumor cell adhesion to the bone microenvironment.
• Specific adhesion molecules mediating skeletal homing of breast cancer cells remain largely unknown, though integrins are suspected.
• The vitronectin receptor (alpha V beta 3) is known to mediate osteoclast-bone recognition, suggesting its potential role in bone metastasis.

Purpose of the Study:

• To investigate the expression of alpha V beta 3 integrin in breast cancer cells metastatic to bone.
• To compare the expression of alpha V beta 3, alpha 2 beta 1, and alpha V beta 5 integrins in primary breast tumors and bone metastases.
• To elucidate the role of specific integrins in the skeletal homing of breast cancer.

Main Methods:

• Systematic immunohistochemistry and in situ hybridization on 22 bone biopsies with breast cancer metastases.
• Analysis of corresponding primary tumor samples and normal breast tissue.
• Comparative assessment of alpha V beta 3, alpha 2 beta 1, and alpha V beta 5 integrin expression and mRNA levels.

Main Results:

• Alpha V beta 3 integrin was strongly expressed in normal breast epithelium, with variable expression in primary invasive breast carcinomas.
• In contrast, alpha V beta 3 integrin was highly abundant in all breast cancer cells metastatic to bone.
• High levels of alpha V beta 3 mRNA correlated with protein expression sites; alpha 2 beta 1 was weakly expressed, and alpha V beta 5 was undetected.

Conclusions:

• Bone-residing breast cancer cells exhibit overexpression of the alpha V beta 3 integrin.
• This overexpression suggests either selection of pre-existing alpha V beta 3-expressing tumor cell subpopulations or upregulation of alpha V beta 3 within the bone microenvironment.
• Alpha V beta 3 integrin is a key molecule potentially involved in breast cancer skeletal metastasis.